Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is related to increasing incidence rates and poor clinical outcomes due to lack of efficient treatment options and emerging resistance mechanisms. The aim of the present study is to exploit a non-viral gene therapy enabling the expression of the parvovirus-derived onco...

Full description

Saved in:
Bibliographic Details
Published in:Journal of controlled release 2021-06, Vol.334, p.138-152
Main Authors: Witzigmann, Dominik, Grossen, Philip, Quintavalle, Cristina, Lanzafame, Manuela, Schenk, Susanne H., Tran, Xue-Ting, Englinger, Bernhard, Hauswirth, Patrick, Grünig, David, van Schoonhoven, Sushilla, Krähenbühl, Stephan, Terracciano, Luigi M., Berger, Walter, Piscuoglio, Salvatore, Quagliata, Luca, Rommelaere, Jean, Nüesch, Jürg P.F., Huwyler, Jörg
Format: Article
Language:English
Subjects:
Gene therapy
Hepatocellular carcinoma
Nanoparticles
Oncotoxic protein
Parvovirus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is related to increasing incidence rates and poor clinical outcomes due to lack of efficient treatment options and emerging resistance mechanisms. The aim of the present study is to exploit a non-viral gene therapy enabling the expression of the parvovirus-derived oncotoxic protein NS1 in HCC. This anticancer protein interacts with different cellular kinases mediating a multimodal host-cell death. Lipoplexes (LPX) designed to deliver a DNA expression plasmid encoding NS1 are characterized using a comprehensive set of in vitro assays. The mechanisms of cell death induction are assessed and phosphoinositide-dependent kinase 1 (PDK1) is identified as a potential predictive biomarker for a NS1-LPX-based gene therapy. In an HCC xenograft mouse model, NS1-LPX therapeutic approach results in a significant reduction in tumor growth and extended survival. Data provide convincing evidence for future studies using a targeted NS1 gene therapy for PDK1 overexpressing HCC. [Display omitted]
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2021.04.023